Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_assertion type Assertion NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_head.
- NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_assertion description "[The goal of the current investigation was to examine a cohort of symptomatic and asymptomatic LRRK2 mutation carriers, in order to address whether the reported alterations in amyloid ? (A?) and tau species in the CSF of patients with sporadic Parkinson disease (PD) are a part of PD pathogenesis, the aging process, or a comorbid disease in patients with PD, and to explore the possibility of A? and tau as markers of early or presymptomatic PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_provenance.
- NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_assertion evidence source_evidence_literature NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_provenance.
- NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_assertion SIO_000772 22170881 NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_provenance.
- NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_assertion wasDerivedFrom befree-2016 NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_provenance.
- NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_assertion wasGeneratedBy ECO_0000203 NP946813.RA1JHoMwdx_ZPPK6-QA1nPS9oKc5wVCSXBcBr6wUQ6XkY130_provenance.